Roxadustat

Roxadustat represents a breakthrough therapeutic class for managing anemia, particularly anemia associated with chronic kidney disease (CKD) . The primary mechanism of Roxadustat involves the reversible and potent inhibition of HIF-prolyl hydroxylase enzymes. Under normal oxygen conditions, these enzymes hydroxylate HIF-α, targeting it for degradation. By inhibiting these enzymes, Roxadustat allows HIF-α to accumulate and translocate to the nucleus, where it dimerizes with HIF-β and activates the transcription of target genes, including the EPO gene . This leads to increased plasma levels of endogenous EPO, mimicking the physiological response to hypoxia. In addition to stimulating EPO production, Roxadustat also improves iron regulation by reducing hepcidin levels and increasing iron transporter proteins, thereby enhancing iron bioavailability and utilization . These combined effects make Roxadustat a comprehensive and orally administered therapy that is transforming the management of anemia in CKD patients.

Product Parameters

Pharmacological Action

Roxadustat is a 4-hydroxyisoquinoline derivative and a small-molecule HIF-PH enzyme inhibitor. HIF is an important transcription factor in the body that adapts to changes in oxygen levels. Under normal oxygen conditions, HIF-PH enzymes promote the degradation of HIF. When the body is hypoxic, the activity of HIF-PH enzymes is inhibited, and the accumulation of HIF increases, thereby inducing the expression of corresponding genes and enabling the body to adapt to the changes caused by hypoxia. Under conditions where the body is not hypoxic, roxadustat inhibits the activity of HIF-PH enzymes, increases the accumulation of HIF, and then produces corresponding physiological responses.

Interaction

Roxadustat has good tolerability and few adverse reactions. In clinical studies, most of its adverse reactions are relatively mild, with common ones including headache, back pain, fatigue, diarrhea, etc. The incidence and severity of adverse reactions have no significant difference compared with the placebo or positive drug control groups, and are mostly related to the patient's own disease state. Compared with the problems of hypertension and vascular embolism caused by EPO, the cardiovascular adverse reactions of roxadustat are more acceptable.

Side Effect

The main side effects of roxadustat include cardiovascular and cerebrovascular issues, such as hypertension, thrombosis, heart failure, etc.; gastrointestinal reactions, such as nausea, vomiting, diarrhea, constipation, etc.; electrolyte abnormalities, such as hyperkalemia, etc.

Contact Us

Looking for Roxadustat to advance your research on anemia and the HIF pathway? Cosperpharm is your trusted partner for high-purity HIF-PH inhibitors. Contact us today to discuss your requirements.